Meta-analysis of the efficacy and safety of daratumumab in the treatment of multiple myeloma

Figure 1  Screening flow chart.

Figure 2  Quality evaluation plot.

Figure 3 Forest plot of the combined results of daratumumab and other therapies in patients with multiple myeloma. A: Progression-free survival time; B: Overall response rate; C: Complete remission; D: Incidence of neutropenia; E: Incidence of anemia; F: Incidence of thrombocytopenia; G: Upper respiratory tract infection; H: Sensitivity analysis. MM: Multiple myeloma; PFS: Progression-free survival time; ORR: Overall response rate; CR: Complete remission; CI: Confidence interval.

Figure 4 Funnel plot of the incidence of adverse event. A: Thrombocytopenia; B: Neutropenia.